The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer
Open accessAbstract
CONTEXT: In addition to classic tumor-related prognostic factors, patient characteristics may be associated with breast cancer outcome. OBJECTIVE: To assess the association between age at diagnosis and breast cancer outcome in postmenopausal women with hormone receptor-positive breast cancer. DESIGN, SETTING, AND PATIENTS: Study analysis of 9766 patients enrolled in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) randomized clinical trial between January 2001 and January 2006. Age at diagnosis was categorized as younger than 65 years (n=5349), 65 to 74 years (n=3060), and 75 years or older (n=1357). MAIN OUTCOME MEASURES: Primary end point was disease-specific mortality; secondary end points were other-cause mortality and breast cancer relapse. RESULTS: During median follow-up of approximately 5.1 years, there were a total of 1043 deaths. Disease-specific mortality, as a proportion of all-cause mortality, decreased with categorical age group (78% [<65 years], 56% [65-74 years], and 36% [≥75 years]; P < .001). In multivariable analyses, compared with patients younger than 65 years, disease-specific mortality increased with age for patients aged 65 to 74 years (hazard ratio [HR], 1.25; 95% CI, 1.01-1.54); and patients aged 75 years or older (HR, 1.63; 95% CI, 1.23-2.16) (P < .001). Similarly, breast cancer relapse increased with age for patients aged 65-74 years (HR, 1.07; 95% CI, 0.91-1.25 and patients aged 75 years or older (HR, 1.29; 95% CI, 1.05-1.60) (P = .06). Other-cause mortality increased with age in patients aged 65 to 74 years (HR, 2.66; 95% CI, 1.96-3.63) and patients aged 75 years or older (HR, 7.30; 95% CI, 5.29-10.07) (P < .001). CONCLUSION: Among postmenopausal women with hormone receptor-positive breast cancer, increasing age was associated with a higher disease-specific mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 1×
“Older patients might respond differently to a tumor than younger patients.(29) In addition, older patients might respond differently to a certain therapy.”
Background
Cited by
Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L. G., Extermann, M., Falandry, C., Artz, A., Brain, E., Colloca, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8347 · Cited by 1,831
Sinn, H.-P., & Kreipe, H. (2013) · Breast Care · doi:10.1159/000350774 · Cited by 403
Zeng, C., Wen, W., Morgans, A. K., Pao, W., Shu, X.-O., & Zheng, W. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.161 · Cited by 321
Estrogen receptors and human disease: an update
Burns, K. A., & Korach, K. S. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0868-5 · Cited by 275
Cheraghi, Z., Poorolajal, J., Hashem, T., Esmailnasab, N., & Doosti Irani, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051446 · Cited by 265
Metadata
- Authors
- van de Water, W., Markopoulos, C., van de Velde, C. J. H., Seynaeve, C., Hasenburg, A., Rea, D., Putter, H., Nortier, J. W. R., de Craen, A. J. M., Hille, E. T. M., Bastiaannet, E., Hadji, P., Westendorp, R. G. J., Liefers, G.-J., & Jones, S. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-02-08
- Volume
- 307
- Issue
- 6
- Pages
- 590-7
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2109569348
- Cited by
- 200
- References
- 2
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.